Edelweiss's research report on Capacite Infraprojects
Capacite Infraprojects (Capacite) has etched a name for itself as a quality contractor in the buildings space since its inception in August 2012; today, it is working with almost all major real estate developers in the country. We be
Toy industry sees opportunity in China's two-child policy Let's call it the people's problem of China. The country's workforce has been shrinking since 2012 -- the fallout from a decades-old policy that restricted most couples to only one child.
Right now, there’s a major shift underway in the biotech field that’s creating a brand-new $59.2 billion industry. And investors who get in now could be positioning themselves for triple- or even quadruple-digit gains…
That’s why we’re bringing readers one of the best biotech stocks to buy in December 2017, according to Money Morning Director of Technology....More>>>
With the Allergan (AGN)-Pfizer (PFE) merger scuttled by those pesky new Treausry rules on tax inversions, Allergan will have a lot of cash on hand to go shopping. Who will it buy? Citigroup’s Liav Abraham and Yigal Nochomovitz have ideas:
Brendan McDermid /Reuters
Current market dynamics, particularly in the SMID biotech universe, provide a plethora of opportunities for the company....More>>>
One of the richest men in China has made a big bet on an icon of Europe’s automotive industry.
Li Shufu, the billionaire chairman of Chinese car maker Geely (GELYF), invested about $9 billion buying a stake of almost 10% in Daimler (DDAIF), making him the biggest single shareholder in the owner of Mercedes Benz.
Li, who’s estimated to be worth around $18 billion, has....More>>>
In no uncertain terms, Snap’s (NYSE:SNAP) first shot at hardware was an utter disaster in just about every way imaginable. Snap ordered far too many units, which resulted in inventory writedowns and other costs associated with canceling its purchase commitments with suppliers. Meanwhile, the company also lost money on each unit sold, and the product failed to generate any type of meaningful....More>>>
China Renaissance, a Beijing investment bank and VC/PE investor, plans to expand its investment funds operations, climbing from $3 billion assets under management currently to $10 billion over the next three years. At the moment, the company runs two funds: Huaxing Growth Capital, focused on technology, media and entertainment, and Huaxing Healthcare. The company plans....More>>>
On Tuesday, our Under the Radar Moversnewsletter suggested small cap clinical-stage biotechnology stock Threshold Pharmaceuticals (NASDAQ: THLD) as a long trade:
The chart below speaks for itself. After trying to work its way above a ceiling at $0.62 for the past several months, that finally happened today, in earnest. Better still, it’s happened after a strong foundation was laid,....More>>>
Shares of Novavax, Inc. (NASDAQ:NVAX), a clinical-stage biotech developing vaccines, have risen about 10.7% as of 3:05 p.m. EDT on Thursday. A positive response to the company’s earnings pushed the stock up a couple days ago, but Thursday’s bump comes in response to recent insider share purchases.
Ligand Pharmaceuticals (NASDAQ:LGND) announced its quarterly earnings results on Tuesday. The biotechnology company reported $1.55 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.98, Bloomberg Earnings reports. The firm had revenue of $56.16 million during the quarter, compared to analysts’ expectations of $43.02 million. Ligand Pharmaceuticals had a net margin....More>>>
Argentine President Mauricio Macri said he will reduce the nation’s fiscal deficit at a faster pace as part of an agreement with the IMF, while acknowledging that inflation targeting had been too ambitious.
An eventual deal with the International Monetary Fund will restore confidence and ensure long-term economic growth, Macri told reporters on Wednesday, following a 23 percent slump....More>>>
With hundreds of biotech stocks on the market, who can keep up with them all? Probably no one. What happens as a result is that usually only the biggest biotechs (or the small biotechs getting bought by the biggest biotechs) get a lot of coverage.But sometimes those aren’t the stocks to watch most closely.
You might not have heard too much about Akebia Therapeutics (NASDAQ:AKBA), BioMarin....More>>>
It has been over two years since I wrote Acceleron Pharma (XLRN) Has Two Potential Blockbusters, so an update is in order. Back then, on July 22, 2015, Acceleron closed at $32.18. It has been very volatile in the meantime, hitting $50.49 on December 29, 2015, but also $21.99 on October 13, 2015. That is part of the thrill (or opportunity, or danger) of investing in clinical-state biotechnology companies.....More>>>
Gene-based therapy is one of the next waves of therapeutic innovation to power this decade and far beyond. The FDA approvals regarding the RNA-based medicines of Sarepta Therapeutics (NASDAQ:SRPT) and the gene-therapy, Luxturna, of Spark Therapeutics (NASDAQ:ONCE) signaled the lowered r
The next-generation of cholesterol drugs -– compounds that inhibit PCSK-9 -– were approved in 2016; these targeted drugs rapidly reduce LDL cholesterol in a wide variety of patients with cardiovascular disease, notes Jay Silverman, editor of The Medical Technology Stock
With three product candidates in the pipeline, at a very early stage, Scholar Rock will need a long time to see the FDA approving them. That said, the company has many patents, a licence with Janssen Biotech, and a fantastic team of professionals. While the risk may be too high for the individua